Heterogeneity of Helicobacter pylori Strains Isolated from Patients with Gastric Disorders in Guiyang, China.

PURPOSE: Chronic Helicobacter pylori infection causes peptic ulcers in a subpopulation of individuals and is a risk factor for the development of gastric cancer. Multiple infections and heteroresistant H. pylori contribute to poor treatment efficacy. Here, we investigated the extent of genetic diversity among H. pylori strains within a given host and its influence on the results of antibiotic (metronidazole, levofloxacin, clarithromycin, amoxicillin, and tetracycline) susceptibility testing. MATERIALS AND METHODS: Gastric mucosa biopsy samples were obtained from patients with gastric disorders, including 48 H. pylori positive patients, who were never previously treated for H. pylori infection. Five potential H. pylori colonies isolated from each sample were subcultured for enrichment. Enriched H. pylori colonies were identified through Gram staining and assays for urease, oxidase, and catalase. For each H. pylori monoclonal colony, the antibiotic susceptibility was assessed, genomic DNA was sequenced, and the cytotoxin-associated gene A (cagA) genotype was verified. Co-infection with multiple H. pylori strains was determined using random amplified polymorphic DNA (RAPD)-polymerase chain reaction (PCR). RESULTS: Thirteen gastric mucosa biopsy samples were positive for H. pylori. Five monoclonal strains isolated from each of these 13 patients were identified as H. pylori. RAPD-PCR indicated that intra-patient monoclonal strains of H. pylori in 10 of the 13 samples exhibited heterogeneity. Among the 13 patients, intra-patient monoclonal strains isolated from 4 patients had identical cagA genotype, whereas intra-patient monoclonal strains isolated from the other 9 patients harbored more than one cagA genotype. The antibiotic susceptibility of five intra-patient monoclonal strains from seven patients was inconsistent. CONCLUSION: The existence of heterogeneous H. pylori strains with resistance to different drugs and virulence were common within the gastric mucosa of an individual patient.

SNP genotyping of enterohemorrhagic Escherichia coli O157:H7 isolates from China and genomic identity of the 1999 Xuzhou outbreak.

Enterohemorrhagic Escherichia coli O157:H7 is a well-known pathogen as a cause of diarrhea, hemorrhagic colitis (HC), and hemolytic uremic syndrome (HUS). Single nucleotide polymorphisms (SNPs) have been widely used to determine genetic relatedness and epidemiological relationship of O157:H7. Little is known of genetic diversity of Chinese O157:H7 isolates and their relationships with global isolates. The minimum sets of 32 SNPs each from Manning et al. and Clawson et al. were used to type 325 Chinese O157:H7 isolates. The 64 SNPs divided the Chinese O157:H7 isolates into 5 SNP genotypes (SG-1-SG-5). The most common SGs were SG-5 (79.69%) and SG-1 (14.46%). Human isolates concentrated in SG-1 and SG-5, and there is only 1 human isolates in SG-3. The 47 isolates in SG-1 were further divided by an additional SNP sourced from Xuzhou21 genome into 2 subtypes (SG-1.1 and SG-1.2). Strains in SG-1.1 caused the 1999 Xuzhou deadly outbreak. Our Chinese isolates have been found to belong to a limited number of SNP genotypes and are represented by distantly related clades in Manning et al. and lineages in Claswon et al., suggesting parallel spread of these SNP genotypes in China.

Antimicrobial activities of recombinant mouse ß-defensin 3 and its synergy with antibiotics.

Mammalian ß-defensins are small cationic peptides of approximately 2-6 kDa that have been implicated in mediating innate immune defenses against microbial infection. This present study investigated the activity of mouse ß-defensin 3 (MBD3) against bacterial and yeast drug-resistant strains in vitro, and whether this molecule acts in synergy with antibiotics. Minimum inhibitory concentrations (MICs) and minimum bactericidal/fungicidal concentrations (MBC/MFC) of recombinant MBD3 (rMBD3) were determined by microdilution assays against different strains of Staphylococcus aureus and Candida albicans. rMBD3 inhibited the growth of S. aureus (MIC, 25 µg/ml) and C. albicans (MIC, 25 µg/ml), and showed fungicidal activity against this yeast (MFC, 100 µg/ml). The influences of rMBD3 on S. aureus and C. albicans cells were examined using electron microscopy. Cells treated with rMBD3 showed morphological and structural changes, including delamination and perforation of the peripheral cell walls, porosity, and inanition of the cytoplasmic contents. Synergistic activities of rMBD3 with different antibiotics were assessed using checkerboard tests. Interestingly, the anti-methicillin-resistant S. aureus activity of rMBD3 in combination with ampicillin was synergistic; however, this was not the case against S. aureus (ATCC 25923). Combinations of rMBD3 with itraconazole, amphotericin or 5-fluorocytosine were synergistic against the two tested C. albicans strains. These results support the interest devoted to defensins as a novel class of antimicrobial agents, and highlight their abilities to potentiate the activities of conventional antibiotics.